Mildronate (Meldonium Dihydrate)

Meldonium inhibits the enzyme responsible for carnitine synthesis, lowering intracellular carnitine levels. This shift reduces fatty‑acid oxidation in heart muscle cells and promotes glucose utilization, which requires less oxygen and improves cardiac efficiency during periods of limited blood flow.

The dosage of Mildronate is determined by the prescribing clinician based on the individual patient's condition, severity of disease and response to therapy. No fixed regimen can be stated; the prescriber sets the appropriate dose and schedule.

Safety data for Meldonium during pregnancy and lactation are limited. Because potential risks cannot be ruled out, the product is generally avoided in pregnant or nursing women unless the prescribing physician determines that the therapeutic benefit outweighs any possible harm.

Enquiries for Mildronate can be submitted through the product page on gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike traditional anti‑anginal agents such as nitrates or beta‑blockers, Mildronate works by modifying myocardial energy metabolism rather than directly affecting vascular tone or heart rate. This distinct mechanism can complement other therapies but may be chosen when metabolic modulation is specifically desired.

Mildronate tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging, protect from moisture and direct heat, and ensure the container is tightly closed to maintain product stability.

Mildronate is supplied as oral tablets intended for ingestion with water. The exact dosing schedule, including frequency and duration, is prescribed by the treating physician and should be followed exactly as instructed.

Serious adverse reactions reported with Mildronate include allergic responses such as rash or anaphylaxis, hepatotoxicity indicated by elevated liver enzymes, and rare cardiac arrhythmias. Patients should be monitored for these events and seek medical attention if they occur.

Mildronate is contraindicated in individuals with known hypersensitivity to Meldonium or any tablet excipients, in patients with severe liver impairment, and generally should be avoided in pregnant or breastfeeding women unless a physician determines that benefits outweigh risks.